Clinical Trials · NCT00615004

Cardiovascular Outcome After Surgery or Somatostatin Analogues

Name: Cardiovascular Outcome After Surgery or Somatostatin Analogues
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedN/AOctreotide Lanreotide

Phase: N/A
Recruitment status: Completed
Sponsor: Federico II University
Enrollment: 215
Start date: Jan 1997
Locations: 1 site, Italy
Primary endpoint: Changes of left ventricular mass index (LVMi), as measure of LV hypertrophy, early to atrial mitral flow velocity (E/A), as measure of diastolic function, and left ventricular ejection fraction (LVEF), as measure of systolic function.

View Octreotide compound reference